Last reviewed · How we verify
metformin 0.85 twice daily for 6 months
metformin 0.85 twice daily for 6 months is a Biguanide Small molecule drug developed by Xiang Guang-da. It is currently FDA-approved for Type 2 diabetes mellitus.
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues, lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin 0.85 twice daily for 6 months |
|---|---|
| Sponsor | Xiang Guang-da |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing glucose uptake and utilization in muscle and adipose tissue. It may also improve insulin secretion from pancreatic beta cells and reduce intestinal glucose absorption. The drug does not stimulate insulin release, making hypoglycemia unlikely when used as monotherapy.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare, in renal impairment)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin 0.85 twice daily for 6 months CI brief — competitive landscape report
- metformin 0.85 twice daily for 6 months updates RSS · CI watch RSS
- Xiang Guang-da portfolio CI
Frequently asked questions about metformin 0.85 twice daily for 6 months
What is metformin 0.85 twice daily for 6 months?
How does metformin 0.85 twice daily for 6 months work?
What is metformin 0.85 twice daily for 6 months used for?
Who makes metformin 0.85 twice daily for 6 months?
What drug class is metformin 0.85 twice daily for 6 months in?
What development phase is metformin 0.85 twice daily for 6 months in?
What are the side effects of metformin 0.85 twice daily for 6 months?
What does metformin 0.85 twice daily for 6 months target?
Related
- Drug class: All Biguanide drugs
- Target: All drugs targeting AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
- Manufacturer: Xiang Guang-da — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: metformin 0.85 twice daily for 6 months vs similar drugs
- Pricing: metformin 0.85 twice daily for 6 months cost, discount & access